Although BARD1 deletions have been reported in patients diagnosed with various cancers, including CRC (Supplementary Table S1), the germline deletion of BARD1 exon 3 represents a novel, previously unreported pathogenic variant. This evidence concerns the gene BARD1 and colorectal carcinoma.